JFG
URGN icon

Jefferies Financial Group’s UroGen Pharma URGN Stock Holding History

Jefferies Financial Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,000
Closed -$411K – 1694
2025
Q2 		$411K Buy
+30,000
New +$288K ﹤0.01% 948

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Jefferies Financial Group's URGN Position: Q1 2026 in Review

Jefferies Financial Group held its UroGen Pharma (URGN) position steady in Q1 2026 at 2,199,652 shares worth $39.5M. The position accounts for 0.27% of the portfolio, ranked #61.

Jefferies Financial Group first reported a position in URGN in Q1 2024 and has held it in 9 quarters since. The position peaked at $51.5M in Q4 2025. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Jefferies Financial Group held 2,199,652 shares of UroGen Pharma worth $39.5M as of Q1 2026.
  • Jefferies Financial Group left its UroGen Pharma share count unchanged in Q1 2026.
  • UroGen Pharma made up 0.27% of Jefferies Financial Group's portfolio in Q1 2026, its #61 holding.
  • Jefferies Financial Group first reported a position in UroGen Pharma in Q1 2024 and has held it in 9 quarters since.
  • Jefferies Financial Group's UroGen Pharma position peaked at $51.5M in Q4 2025.
  • 172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.